Io-EMP (790461)
https://cordis.europa.eu/project/id/790461
Horizon 2020 (2014-2020)
Tissue-derived acellular micro-scaffold technology reducing or eliminating diabetics’ dependence on insulin therapy
Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs (SMEInst-02-2016-2017)
diabetic nephropathy · immunology · stem cells · retinopathy · cerebrovascular diseases
2017-11-01 Start Date (YY-MM-DD)
2018-02-28 End Date (YY-MM-DD)
€ 71,429 Total Cost
Description
Betalin’s mission is to provide a tissue-derived acellular micro-scaffold that will extend the life and the insulin-producing performance of transplanted beta cells in order to reduce or eliminate the dependence of some diabetics on insulin therapy. Type 1 Diabetes is a chronic disease that results from the autoimmune destruction of the insulin-producing beta cells in the pancreas. Its cause is still uncertain and there is no known way to prevent its onset. With~70,000 new cases diagnosed each year, it is estimated that ~17 mn people worldwide are afflicted with T1DM. In the US alone, T1DM results in $14.4 bn in medical costs and lost income annually. Type 1 diabetics face a lifetime regime of insulin therapy and very careful lifestyle management in an attempt to mitigate the long-term complications associated with T1DM such as cardiovascular disease, damage to the eyes, kidneys and nerves, and premature death. In recent years islet transplantation has been researched as a treatment for T1DM. The procedure involves injecting millions of islets (the pancreatic cell clusters that “house” the insulinproducing beta cells) harvested from cadavers, followed by immunosuppression therapy. Islet transplantation is a promising approach but the naked islets are very unstable: they must be transplanted almost immediately after harvesting and up to 80% of the transplanted islets stop functioning within 24hrs. The result is that, after five years, less than 10% of the recipients are free of daily insulin treatment. Betalin’s technology is based on the premise that in order for beta cells to function properly it is necessary to provide an appropriate stromal (connective tissue) micro-environment. The proprietary platform technology is a method to prepare acellular organ-derived micro-scaffolds that preserve the architecture and the basic composition of organ stroma and ensure that no seeded cell will be more than 150 microns from a source of nutrients and gases.
Complicit Organisations
1 Israeli organisation participates in Io-EMP.Country | Organisation (ID) | VAT Number | Role | Activity Type | Total Cost | EC Contribution | Net EC Contribution |
---|---|---|---|---|---|---|---|
Israel | BETALIN THERAPEUTICS LTD (916614693) | IL515274272 | coordinator | PRC | € 71,429 | € 50,000 | € 50,000 |